Immunocytochemical demonstration of growth hormone in pituitary adenoma.

N. Halmi,T. Duello

DOI: https://doi.org/10.1016/S0022-3476(78)80186-3

IF: 2.99

1978-05-01

Jornal de Pediatria

Abstract:

What problem does this paper attempt to address?

Adrenomedullin expression in pituitary adenomas and nontumoral adenohypophyses

M Lombardero,K Kovacs,E Horvath,B W Scheithauer,F Rotondo,F Salehi,R V Lloyd

DOI: https://doi.org/10.14670/HH-23.11

Abstract:Adrenomedullin (ADM) is a novel peptide originally identified in extracts of human pheochromocytoma. It is produced by several tissues, including the pituitary gland. The presence of ADM has been immunohistochemically demonstrated in pathologic pituitary glands, but no systematic study of ADM expression in human pituitary adenomas has been reported. Thus, we investigated ADM immunoexpression in 88 various hormone-secreting and clinically nonfunctioning pituitary adenoma types as well as 30 nontumoral adenohypophyses. Furthermore, ADM immunoreactivity was assessed on a 0 to +3 scale in all samples. We found strong immunoreativity for ADM in normal gonadotrophs also expressing FSH and LH whereas in the other adenohypophysial cell types expression of ADM was mild. Results showed that normal adenohypophyses were strongly immunopositive for ADM (2.18+/-0.11). Our findings demonstrate that ADM expression in the anterior pituitary is diminished in tumors as compared to the normal gland. The physiologic function of ADM is unknown, but it could act as a paracrine or autocrine factor in the adenohypophysis.
[Clinical Analysis of 13 Cases with Growth Hormone Deficiency Combined with Pituitary Stalk Interruption].

Gao-liang Wang,Jun-fen Fu,Chun-lin Wang,Li Liang

DOI: https://doi.org/10.3760/cma.j.issn.0578-1310.2010.04.016

2010-01-01

Abstract:OBJECTIVE:To analyze the clinical characteristics of the patients with pituitary stalk interruption syndrome (PSIS), and to achieve better comprehension of this disease.METHOD:Data of 13 patients with PSIS were retrospectively analyzed for the clinical, laboratory and imaging features.RESULT:All the 13 patients (9 male, 4 female) had the chief complaint of growth retardation, 81.5 - 135.0 cm in body height, which were minus two standard deviations below the average of the normal children of same age and same sex. GH stimulated peak levels were all below 5 microg/L; Among them, one was accompanied by delayed sexual development, one by central diabetes insipidus, one was complicated with central hypothyroidism and one was accompanied by central adrenocortical hypofunction.CONCLUSION:The most remarkable clinical manifestations of patients with PSIS were growth retardation, partial or complete adenohypophyseal dysfunction. MRI revealed absence of pituitary stalk or anterior pituitary hypoplasia with ectopic posterior pituitary gland.
Growth Hormone Receptor Expression in the Dunning R 3327 Prostatic Carcinoma of the Rat.

F SINOWATZ,W BREIPOHL,MI WATERS,D LINCOLN,PE LOBIE,W AMSELGRUBER

DOI: https://doi.org/10.1002/pros.2990190402

1991-01-01

Abstract:The Dunning R3327 rat carcinoma is an important model for human prostate adenocarcinoma. In the present study this tumor was further characterized by immunohistochemical demonstration of receptors for growth hormone (GH-R). Weak GH-R immunoreactivity was present in the secretory epithelial cells of the tumor acini. Large epithelial cells which were localized at the periphery of the acini and large cells in the stroma, which are probably derived from the epithelium ("Large neoplastic epithelial cells"), displayed a strong staining with one of the monoclonal antibodies (Mab 263) to GH-R. The presence of GH-R receptors in proliferating prostatic tumor cells supports the concept that GH reacts directly on prostate target tissue to facilitate tumor cell growth.
Growth Hormone Receptor Expression in the Rat Gastrointestinal Tract

Lobie P E,Breipohl W,Waters M J

DOI: https://doi.org/10.1210/endo-126-1-299

IF: 5.051

1990-01-01

Endocrinology

Abstract:We have used immunohistochemistry to define the cellular distribution of GH receptors in the gastrointestinal tract (GIT) and its derivatives. Immunohistochemistry was performed in the adult rat GIT with a panel of characterized monoclonal antibodies to the GH receptor. The most intense and heterogeneous immunoreactivity was observed in epithelial cell subpopulations of GIT mucosa. Mesenchymal elements of the GIT were homogenously and moderately immunoreactive. Intense immunoreactivity was observed in the ductal epithelium of the sublingual gland, scattered basal epidermal cells of the esophageal mucosa, zymogen cells of the gastric glands, scattered surface epithelial cells of the stomach, and scattered peripheral pancreatic acinar groups. Scattered enteroendocrine cells and parietal cells, crypt and villous columnar cells of the small intestine, surface columnar cells of the cecum/colon, crypt base columnar cells of the colon, and contiguous peripheral cords of pancreatic islet cells displayed strong immunoreactivity. No immunoreactivity was detectable in the mucous and serous acini of the sublingual and submandibular gland, respectively, mucous-secreting cells of the base of the cardiac and pyloric glands, surface epithelial cells of the fundus, paneth cells, goblet cells of cecum/colon, or mucous cells at the base of the cecal crypt. Other elements of the GIT were moderately or weakly immunoreactive. In support of our localization we can detect high affinity binding (Ka = 3 x 10(9] of [125I]human GH with ovine GH as displacing ligand to crude homogenates of adult rat stomach and intestine. We conclude that discrete epithelial cell subpopulations of the GIT and its derivatives are directly responsive to GH action. GH may, therefore, act independently of or synergistically with hepatic insulin-like growth factor-I in executing its physiological and/or growth-promoting role in the GIT.
Immunohistochemical expression of neuroendocrine secretory protein-55 (NESP-55) in pituitary adenomas

Mamta Gupta,Ricardo V Lloyd,Reiner Fischer-Colbrie,Arthur S Tischler,Yogeshwar Dayal

DOI: https://doi.org/10.1007/s12022-011-9162-y

Abstract:Neuroendocrine secretory protein-55 (NESP-55) is a recently described member of the chromogranin family and appears to be a marker of the constitutive secretory pathway in certain neural, neuroendocrine, and endocrine cell types. It has been shown to be selectively expressed in tumors differentiating towards the adrenal chromaffin and pancreatic islet cell phenotypes. The highest levels of NESP-55 expression, at least in animals, appear to be in the adrenal medulla and the pituitary gland. However, very little is known about the status of NESP-55 expression in pituitary adenomas. We therefore studied the immunohistochemical profile of NESP-55 expression in a series of 30 well-characterized pituitary adenomas (five each of FSH/LH and ACTH, four GH, three TSH, seven prolactin, and six null cells). All tumors were positive for one or more generic marker(s) (chromogranin A, synaptophysin, neuron-specific enolase) of neuroendocrine differentiation. All pituitary adenomas selected for study were stained for NESP-55 with appropriate positive and negative controls. NESP-55 immunoreactivity, seen as brown finely granular cytoplasmic staining of the tumor cells with prominent perinuclear accentuation, was graded as focal (<10% tumor cells staining), moderate (10-50% tumor cells staining), and diffuse (>50% tumor cell staining). Four of seven prolactinomas were positive for NESP-55 (one focal, two moderate, and one diffuse). Two of four GH adenomas were also positive (one focal and one diffuse) while only 1/5 FSH tumors showed a moderately intense immunoreactivity. All other pituitary adenomas were completely negative for NESP-55. Our results indicate that, in human pituitary adenomas, NESP-55 has a more restricted pattern of expression than that of chromogranins A and B. Since immunohistochemical expression of NESP-55 is largely confined to prolactinomas and GH adenomas, it raises the possibility that NESP-55 may somehow be involved in the secretory pathways of these specific cell types.
Growth Hormone Releasing Hormone in Human GH-secreting Adenoma

SHEN Ye,HU Ji,ZHANG Yu-lin,WANG Xuan-chun,CHEN Fen-ling,LIU Yu,HU Ren-ming

DOI: https://doi.org/10.3969/j.issn.1672-8467.2006.04.009

2006-01-01

Abstract:Purpose To investigate Gsα and growth hormone releasing hormone receptor(GHRHR)mutation and the possible role of GHRH in the formation of human pituitary somatotroph adenoma. Methods Pituitary adenomas from 26 patients were studied for GHRH and GHRHR expressions by immunohistochemical method.DNA were extracted from pituitary adenoma tissue,and the products of PCR(Gsα and GHRHR) were sequenced. Results We found positivity expression of GHRH in 4 paraffin-embedded tissues(15.4%) and GHRHR in 8 tissues(30.8%).Three of the 26 GH-secreting adenomas had point mutations in codon 201 or 210,two in codon 201 and one was in codon 210;two mutations of GHRHR were detected in codon 225. Conclusions Genetic abnormalities such as Gsα mutation might lead to the formation of GH-secreting adenoma.It was postulated that GHRH produced by the somatotroph adenoma cells might play a role in the pathogenesis of GH-secreting adenoma by autocrine or pancrine mechanism.
Vascular endothelial growth factor (VEGF) expression in human pituitary adenomas and carcinomas

Ricardo V. Lloyd,Bernd W. Scheithauer,Takao Kuroki,Sergio Vidal,Kalman Kovacs,Lucia Stefaneanu

DOI: https://doi.org/10.1007/bf02738884

1999-09-01

Endocrine Pathology

Abstract:Vascular endothelial growth factor (VEGF) is a key mediator of endothelial cell proliferation, angiogenesis, and vascular permeability. Little is known about its expression in human pituitary adenomas.We examined 148 human pituitary adenomas for VEGF protein expression by immunohistochemistry. The strongest immunoreactivity was present in GH adenomas, corticotroph, silent corticotroph, silent subtype 3, and nononcocytic null cell adenomas. GH adenomas treated with octreotide strained less intensely than did untreated tumors. Relatively weak staining was present in PRL, gonadotroph, thyrotroph, and oncocytic null cell adenomas in the same sections showed evidence of down-regulation of VEGF protein expression in adenomas. Pituitary carcinomas usually had stronger staining than adenomas.In situ hybridization studies with oligonucleotide probes showed positive staining in all groups with stronger staining in GH, ACTH, TSH, and gonadotroph adenomas and in pituitary carcinomas.These results indicate that VEGF expression is more prominent in certain adenoma subtypes, that decreased expression occurs in adenomas as compared to nontumorous pituitary and that carcinomas show increased VEGF expression relative to adenomas suggesting up-regulation of VEGF during pituitary tumor progression.

pathology,endocrinology & metabolism
Mixed Gangliocytoma/pituitary Adenoma: a Clinicopathologic Study of Four Cases and Review of Literature

LU Hong-sheng,SHI Qun-li,ZHOU Xiao-jun,MA Heng-hui,MENG Kui,LU Zhen-feng

DOI: https://doi.org/10.3969/j.issn.1001-7399.2005.04.004

2005-01-01

Abstract:Purpose To investigate the pathogenesis, clinicopathological characteristics, diagnosis and differential diagnosis of the mixed gangliocytoma/pituitary adenoma (MGPA). Methods Four cases of MGPA were studied with HE and immunohistochemical EnVision-plus staining. Results All patients were female, with age ranged from 10 to 35 years (mean 26.5 years). Clinically, three cases were endocrinologically symptomatic and one case was falling sickness. Histopathologically, two distinct neoplastic cell populations were observed in the same tumor mass. The first population was composed of many ganglionic cells showing large nuclei, prominent nucleoli, and Nissl bodies, which were positive for CgA, Syn, S-100 protein and negative for GFAP. The second population was similar cells in sizes and shapes, with round-oval nuclei, abundant and acidophilic or pale cytoplasm, which were immunoreactive for GH and PRL. Conclusions MGPA is a very rare mixed pituitary tumor with good prognosis. It arises mostly on young woman presenting with acromegaly. The diagnosis depends mainly on HE as well as immunohistochemical staining.
Molecular Morphology of Pituitary Cells, from Conventional Immunohistochemistry to Fluorescein Imaging

Akira Matsuno,Akiko Mizutani,Hiroko Okinaga,Koji Takano,So Yamada,Shoko M. Yamada,Hiroshi Nakaguchi,Katsumi Hoya,Mineko Murakami,Masato Takeuchi,Mutsumi Sugaya,Johbu Itoh,Susumu Takekoshi,R. Yoshiyuki Osamura

DOI: https://doi.org/10.3390/molecules16053618

IF: 4.6

2011-04-29

Molecules

Abstract:In situ hybridization (ISH) at the electron microscopic (EM) level is essential for elucidating the intracellular distribution and role of mRNA in protein synthesis. EM-ISH is considered to be an important tool for clarifying the intracellular localization of mRNA and the exact site of pituitary hormone synthesis on the rough endoplasmic reticulum. A combined ISH and immunohistochemistry (IHC) under EM (EM-ISH&IHC) approach has sufficient ultrastructural resolution, and provides two-dimensional images of the subcellular localization of pituitary hormone and its mRNA in a pituitary cell. The advantages of semiconductor nanocrystals (quantum dots, Qdots) and confocal laser scanning microscopy (CLSM) enable us to obtain three-dimensional images of the subcellular localization of pituitary hormone and its mRNA. Both EM-ISH&IHC and ISH & IHC using Qdots and CLSM are useful for understanding the relationships between protein and mRNA simultaneously in two or three dimensions. CLSM observation of rab3B and SNARE proteins such as SNAP-25 and syntaxin has revealed that both rab3B and SNARE system proteins play important roles and work together as the exocytotic machinery in anterior pituitary cells. Another important issue is the intracellular transport and secretion of pituitary hormone. We have developed an experimental pituitary cell line, GH3 cell, which has growth hormone (GH) linked to enhanced yellow fluorescein protein (EYFP). This stable GH3 cell secretes GH linked to EYFP upon stimulation by Ca²+ influx or Ca²+ release from storage. This GH3 cell line is useful for the real-time visualization of the intracellular transport and secretion of GH. These three methods from conventional immunohistochemistry and fluorescein imaging allow us to consecutively visualize the process of transcription, translation, transport and secretion of anterior pituitary hormone.

chemistry, multidisciplinary,biochemistry & molecular biology
Immunohistochemical localization of huntingtin-associated protein 1 in endocrine system of the rat.

Min Liao,Jianying Shen,Yinong Zhang,Shi-Hua Li,Xiao-Jiang Li,He Li

DOI: https://doi.org/10.1369/jhc.5a6662.2005

2005-01-01

Abstract:Huntingtin-associated protein 1 (HAP1) was originally found to be localized in neurons and is thought to play an important role in neuronal vesicular trafficking and/or organelle transport. Based on functional similarity between neuron and endocrine cell in vesicular trafficking, we examined the expression and localization of HAP1 in the rat endocrine system using immunohistochemistry. HAP1-immunoreactive cells are widely distributed in the anterior lobe of the pituitary, scattered in the wall of the thyroid follicles, or clustered in the interfollicular space of the thyroid gland, exclusively but diffusely distributed in the medullae of adrenal glands, and selectively located in the pancreas islets. HAP1-containing cells were also found in the mucosa of stomach and small intestine with a distributive pattern similar to that of gastrointestinal endocrine cells. However, no HAP1-immunoreactive cell was found in the cortex of the adrenal gland, the testis, and the ovary. In the posterior lobe of the pituitary, HAP1-immunoreactive products were not detected in the cell bodies but in many stigmoid bodies, one kind of non-membrane-bound cytoplasmic organelle with a central or eccentric electron-lucent core. HAP1-immunoreactive stigmoid bodies were also found in the cytoplasm of endocrine cells in the thyroid gland, the medullae of adrenal gland, the pancreas islets, the stomach, and small intestine. The present study demonstrates that HAP1 is selectively expressed in part of the small peptide-, protein-, and amino-acid analog and derivative-secreting endocrine cells but not in steroid hormone-secreting cells, suggesting that HAP1 is also involved in intracellular trafficking in certain types of endocrine cells.
Cellular Expression of Growth Hormone and Prolactin Receptors in Human Breast Disorders

HC Mertani,T Garcia-Caballero,A Lambert,F Gerard,C Palayer,JM Boutin,BK Vonderhaar,MJ Waters,PE Lobie,G Morel

DOI: https://doi.org/10.1002/(sici)1097-0215(19980417)79:2<202::aid-ijc17>3.3.co;2-

1998-01-01

International Journal of Cancer

Abstract:Growth hormone (GH) and prolactin (PRL) exert their regulatory functions in the mammary gland by acting on specific receptors. Using isotopic in situ hybridization and immunohistochemistry, we have localized the expression of hGH receptor (hGHR) and hPRL receptor (hPRLR) in a panel of human breast disorders. Surgical specimens from adult females included normal breast, inflammatory lesions (mastitis) benign proliferative breast disease (fibroadenoma, papilloma, adenosis, epitheliosis), intraductal carcinoma or lobular carcinoma in situ, and invasive ductal, lobular or medullary carcinoma. Cases of male breast enlargement (gynecomastia) were also studied. In situ hybridization analysis demonstrated the co-expression of hGHR and hPRLR mRNA in all samples tested. Epithelial cells of both normal and tumor tissues were labelled. Quantitative estimation of receptor mRNA levels was regionally measured in areas corresponding to tumor cells and adipose cells from the same section. It demonstrated large individual variation and no correlation emerged according to the histological type of lesion. Receptor immunoreactivity was detected both in the cytoplasm and nuclei or in the cytoplasm alone. Scattered stromal cells were found positive in some cases, but the labeling intensity was always weaker than for neoplastic epithelial cells. Our results demonstrate the expression of the hGHR and hPRLR genes and their translation in epithelial cells of normal, proliferative and neoplastic lesions of the breast. They also demonstrate that stromal components express GHR and PRLR genes. Thus the putative role of hGH or hPRL in the progression of proliferative mammary disorders is not due to grossly altered levels of receptor expression.
Functional molecular morphology of anterior pituitary cells, from hormone production to intracellular transport and secretion

Akira Matsuno,Akiko Mizutani,Hiroko Okinaga,Koji Takano,So Yamada,Shoko M. Yamada,Hiroshi Nakaguchi,Katsumi Hoya,Mineko Murakami,Masato Takeuchi,Mutsumi Sugaya,Johbu Itoh,Susumu Takekoshi,R. Yoshiyuki Osamura

DOI: https://doi.org/10.1007/s00795-011-0545-4

2011-06-01

Medical Molecular Morphology

Abstract:Combined in situ hybridization (ISH) and immunohistochemistry (IHC) under electron microscopy (EM-ISH & IHC) has sufficient ultrastructural resolution to provide two-dimensional images of subcellular localization of pituitary hormone and its mRNA in a pituitary cell. The advantages of semiconductor nanocrystals (Quantum dots; Qdots) and confocal laser scanning microscopy (CLSM) enable us to obtain three-dimensional images of the subcellular localization of pituitary hormone and its mRNA. Both EM-ISH & IHC and ISH & IHC using Qdots and CLSM are useful for understanding the relationship between protein and mRNA simultaneously in two or three dimensions. CLSM observation of rab3B and SNARE proteins such as SNAP-25 and syntaxin revealed that both rab3B and SNARE system proteins play an important role and work together as the exocytotic machinery in anterior pituitary cells. Another important issue is the intracellular transport and secretion of pituitary hormone. An experimental pituitary cell line, the GH3 cell, in which growth hormone (GH) is linked to enhanced yellow fluorescein protein (EYFP), has been developed. This stable GH3 cell secretes GH linked to EYFP upon being stimulated by Ca2+ influx or Ca2+ release from storage. This GH3 cell is useful for real-time visualization of the intracellular transport and secretion of GH. These three methods enable us to visualize consecutively the processes of transcription, translation, transport, and secretion of pituitary hormone.

pathology
Analyses of the mechanism of intracellular transport and secretion of pituitary hormone, with an insight of the subcellular localization of pituitary hormone and its mRNA

Akira Matsuno,Akiko Mizutani,Susumu Takekoshi,Johbu Itoh,Hiroko Okinaga,Yuko Nishina,Koji Takano,Tadashi Nagashima,R Yoshiyuki Osamura,Akira Teramoto

DOI: https://doi.org/10.1007/s10014-005-0189-y

Abstract:Combined in situ hybridization (ISH) and immunohistochemistry (IHC) under electron microscopy (EM-ISH&IHC) has sufficient ultrastructural resolution and provides two-dimensional images of subcellular localization of pituitary hormone and its mRNA in a pituitary cell. The advantages of semiconductor nanocrystals (Quantum dots, Qdots) and confocal laser scanning microscopy (CLSM) enable us to obtain three-dimensional images of subcellular localization of pituitary hormone and its mRNA. Both EM-ISH&IHC and ISH&IHC using Qdots and CLSM are useful for understanding the relation between protein and mRNA simultaneously in two or three dimensions. Another important issue is the intracellular transport and secretion of pituitary hormone. We have developed an experimental pituitary cell line, the GH3 cell, which has growth hormone (GH) linked to enhanced yellow fluorescein protein (EYFP). This stable GH3 cell secretes GH linked to EYFP upon stimulated by Ca2+ influx or Ca2+ release from storage. This GH3 cell is useful for real-time visualization of the intracellular transport and secretion of GH. These three methods enable us to visualize consecutively the process of transcription, translation, transport, and secretion of pituitary hormone.
Morpho-Molecular Metabolic Analysis and Classification of Human Pituitary Gland and Adenoma Biopsies Based on Multimodal Optical Imaging

Gabriel Giardina,Alexander Micko,Daniela Bovenkamp,Arno Krause,Fabian Placzek,Laszlo Papp,Denis Krajnc,Clemens P Spielvogel,Michael Winklehner,Romana Höftberger,Greisa Vila,Marco Andreana,Rainer Leitgeb,Wolfgang Drexler,Stefan Wolfsberger,Angelika Unterhuber

DOI: https://doi.org/10.3390/cancers13133234

2021-06-29

Abstract:Pituitary adenomas count among the most common intracranial tumors. During pituitary oncogenesis structural, textural, metabolic and molecular changes occur which can be revealed with our integrated ultrahigh-resolution multimodal imaging approach including optical coherence tomography (OCT), multiphoton microscopy (MPM) and line scan Raman microspectroscopy (LSRM) on an unprecedented cellular level in a label-free manner. We investigated 5 pituitary gland and 25 adenoma biopsies, including lactotroph, null cell, gonadotroph, somatotroph and mammosomatotroph as well as corticotroph. First-level binary classification for discrimination of pituitary gland and adenomas was performed by feature extraction via radiomic analysis on OCT and MPM images and achieved an accuracy of 88%. Second-level multi-class classification was performed based on molecular analysis of the specimen via LSRM to discriminate pituitary adenomas subtypes with accuracies of up to 99%. Chemical compounds such as lipids, proteins, collagen, DNA and carotenoids and their relation could be identified as relevant biomarkers, and their spatial distribution visualized to provide deeper insight into the chemical properties of pituitary adenomas. Thereby, the aim of the current work was to assess a unique label-free and non-invasive multimodal optical imaging platform for pituitary tissue imaging and to perform a multiparametric morpho-molecular metabolic analysis and classification.
Localization Of The Growth-Hormone Receptor-Binding Protein In Skin

P. E. Lobie,W. Breipohl,D. T. Lincoln,J García-Aragón,M. J. Waters

DOI: https://doi.org/10.1677/joe.0.1260467

1990-01-01

Journal of Endocrinology

Abstract:Acromegaly is characterized by coarsening of facial features, acanthosis nigricans, hypertrichosis and oily skin. To determine the site through which GH exerts these effects, we have used immunohistochemistry to localize the GH receptor/binding protein (BP) in rat, rabbit and human skin. Three monoclonal antibodies (MAb 1, 43, 263) were immunoreactive in identical locations, whereas no immunoreactivity was evident when control monoclonal antibodies (MAb 50.8 and MAb 7 (rat] were used. Skin from neonatal and adult animals was used to determine whether GH receptor/BP expression was developmentally regulated. Immunoreactivity of the GH receptor/BP in the three species was consistently localized in the stratum basale and stratum spinosum. Intermittent staining was observed in the stratum granulosum. Scattered basal epidermal cells often displayed more intense immunoreactivity. This distribution was observed at all maturational stages examined. Intense GH receptor/BP immunoreactivity was observed in all histological layers of the lower one-third of hair follicles and in hair matrix cells of the dermal papillae. Immunoreactivity was also detected in the outer epithelial root sheath of the upper two-thirds of hair follicles, in sebaceous glands and in fibroblasts of the connective tissue sheath surrounding the follicle. GH receptor/BP immunoreactivity was also present in the secretory duct and myoepithelial cells of human eccrine sweat glands. Fibroblasts, Schwann cells of peripheral nerve fascicles, skeletal muscle cells and adipocytes of the dermis were also immunoreactive as were medial smooth muscle and endothelial cells of arteries. These results provide evidence that GH acts locally on the epidermis and epidermal appendages concordant with our recent localization of GH receptor/BP to epithelial cell types of the gastrointestinal and reproductive systems.
Immunohistochemical analysis of ghrelin expression in various types of adrenal tumors

Hanna Komarowska,Agnieszka Malinska,Zhanat Komekbai,Barbara Brominska,Katarzyna Bednarek-Rajewska,Marek Ruchala,Marcin Rucinski

DOI: https://doi.org/10.5603/FHC.a2021.0009

Abstract:Introduction: Ghrelin, originally isolated from the endocrine cells of the gastric mucosa, is also expressed in many peripheral tissues, including normal adrenals and adrenocortical tumors. It was shown that ghrelin stimulates proliferation and inhibits apoptosis of adrenocortical cells. In the current study, we compared ghrelin expression at the protein level in various adrenal tumors. We analyzed whether immunoreactive ghrelin could be considered as a potential marker for different types of adrenal tumors. Material and methods: Study was carried out on 200 adrenal specimens arranged on microscope slide in tissue microarray format. We performed standardized immunohistochemical reactions with semiquantitative reaction intensity measurements. Results: At the protein level, the expression of ghrelin was significantly reduced in adrenocortical adenocarcinoma in relation to the control group and pheochromocytoma as well as cancer-adjacent normal adrenal tissue. In contrast, a relatively high ghrelin expression was found in pheochromocytoma compared to all analyzed groups, with the exception of cancer-adjacent normal adrenal tissue. Conclusions: The ghrelin expression profile at the protein level may be associated with the type of adrenal tumor. In this context, our results suggest that adrenal immunoreactive ghrelin may be considered as a sensitive and specific marker for differentiating adrenocortical carcinoma from adrenocortical adenoma and pheochromocytoma.
Immunohistochemical and Ultrastructural Features Researches of Hypothalamic Hamartoma

SUN Yi-lin,LUO Shi-qi,ZHANG Hui,WAN Hong,PENG Ji-ying,WANG Xing-cui,QU Bao-qing,MA Zhen-yu,LI Chun-de

DOI: https://doi.org/10.3969/j.issn.1000-6281.2005.05.013

2005-01-01

Abstract:Forty-seven operative samples of hypothalamic hamartoma accompanied with precocious puberty and pelastic epilepsy were observed under electron microscope and stained by anti-GnRH antibody with immunohistochemistry method.It is identified that the hypothalamic hamartoma is labeled by anti-GnRH antibody,implying the tumor is able to secrete GnRH.Electron microscopic observation shown that nerve cells in the tumor tissues were heteromorphies,there were a great number of neurotubules and synapse-like endings containing a plenty of small round clear neurotransmitter vesicles and few dense core secretory granules were seen in the neuropil.It was suggest that these ultrastructural features were in association with the precocious puberty and pelastic epilepsy.
The Nuclear Growth Hormone Receptor Binding Protein. Antigenic and Physicochemical Characterization.

PE LOBIE,R BARNARD,MJ WATERS

DOI: https://doi.org/10.1016/s0021-9258(18)54619-6

IF: 5.485

1991-01-01

Journal of Biological Chemistry

Abstract:The mechanisms involved in transcriptional regulation by growth hormone (GH) remain unknown. We report here that GH receptor immunoreactivity can be demonstrated in the nuclei of GH-responsive rat and rabbit tissues at both the light and electron micrograph level using monoclonal antibodies to the receptor extracellular domain. Nuclear staining is heterogeneous and associated with both chromatin and the nuclear membrane. To confirm these observations, nuclei were isolated from rabbit liver by two methods, one involving extensive nonionic detergent washes. Scatchard analysis of nuclear fractions revealed high affinity somatogenic receptor in nuclear membranes, nucleoplasm, and chromatin fractions. A panel of GH receptor monoclonal antibodies was used to further define these nuclear binding sites as being antigenically identical to microsomal receptor in all but one case. In addition, affinity cross-linking experiments showed the somatogenic binding subunit to have a reduced Mr of 67,000, similar to the Mr of the GH binding protein. We propose that the association of a GH binding protein with the nucleus may provide a means whereby GH can regulate the transcription of specific genes either directly or indirectly through nuclear kinase C activation. This speculation is congruent with the recent demonstration of a GH response element by Yoon et al. (Yoon, J. B., Berry, S. A., Seelig, S., and Towle, H. C. (1990) J. Biol. Chem. 265, 19947-19954).
Clinical and molecular studies of a thyrotropin-secreting pituitary adenoma

M H Samuels,W M Wood,D F Gordon,B K Kleinschmidt-DeMasters,K Lillehei,E C Ridgway

DOI: https://doi.org/10.1210/jcem-68-6-1211

Abstract:A 40-year-old woman, who had previously received radioactive iodine for hyperthyroidism, presumably due to Graves' disease, subsequently was found to have inappropriately elevated serum TSH and alpha-subunit levels and a pituitary adenoma. Detailed clinical studies revealed marked serum TSH elevations (approximately 100 mU/L) with no circadian variation, but with 7 pulses/24 h. Serum alpha-subunit levels averaged 2.5 micrograms/L, with 13 pulses/24 h. Neither serum TSH nor alpha-subunit responded to TRH stimulation, nor did serum TSH change during dopamine infusion, but alpha-subunit levels did decline slightly. In contrast, during somatostatin infusion, serum TSH declined to 30% of baseline levels, while alpha-subunit levels did not change. Pituitary adenoma tissue obtained at the time of transsphenoidal surgery immunostained weakly with anti-TSH beta serum and strongly with anti-alpha-subunit serum. Northern blot analysis of RNA isolated from the tumor revealed TSH beta and alpha-subunit mRNA levels of normal length, while primer extension analysis showed a major initiation site for the TSH beta gene that appeared to be identical in the tumor and normal pituitary tissue. A second minor upstream start site was detected in the tumor, but it represented less than 1% of transcription compared to the major downstream start site. We conclude that the tumor secreted TSH and alpha-subunit in an abnormal and discordant fashion, but that the TSH gene initiation site appeared to be normal and, therefore, did not explain the observed secretory abnormalities.

Immunocytochemical demonstration of growth hormone in pituitary adenoma.

Adrenomedullin expression in pituitary adenomas and nontumoral adenohypophyses

[Clinical Analysis of 13 Cases with Growth Hormone Deficiency Combined with Pituitary Stalk Interruption].

Growth Hormone Receptor Expression in the Dunning R 3327 Prostatic Carcinoma of the Rat.

Growth Hormone Receptor Expression in the Rat Gastrointestinal Tract

Immunohistochemical expression of neuroendocrine secretory protein-55 (NESP-55) in pituitary adenomas

Growth Hormone Releasing Hormone in Human GH-secreting Adenoma

Vascular endothelial growth factor (VEGF) expression in human pituitary adenomas and carcinomas

Mixed Gangliocytoma/pituitary Adenoma: a Clinicopathologic Study of Four Cases and Review of Literature

Molecular Morphology of Pituitary Cells, from Conventional Immunohistochemistry to Fluorescein Imaging

Immunohistochemical localization of huntingtin-associated protein 1 in endocrine system of the rat.

Cellular Expression of Growth Hormone and Prolactin Receptors in Human Breast Disorders

Functional molecular morphology of anterior pituitary cells, from hormone production to intracellular transport and secretion

Analyses of the mechanism of intracellular transport and secretion of pituitary hormone, with an insight of the subcellular localization of pituitary hormone and its mRNA

Morpho-Molecular Metabolic Analysis and Classification of Human Pituitary Gland and Adenoma Biopsies Based on Multimodal Optical Imaging

Localization Of The Growth-Hormone Receptor-Binding Protein In Skin

Immunohistochemical analysis of ghrelin expression in various types of adrenal tumors

Immunohistochemical and Ultrastructural Features Researches of Hypothalamic Hamartoma

The Nuclear Growth Hormone Receptor Binding Protein. Antigenic and Physicochemical Characterization.

Clinical and molecular studies of a thyrotropin-secreting pituitary adenoma